Pfizer RSV vaccine may protect high-risk adults ages 18-59

Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.

Related Keywords

Japan ,United States ,Americans ,Iona Munjal ,Glaxosmithkline ,Pfizer ,Respiratory Syncytial Virus ,Breaking News ,Gsk Plc ,Science ,Pfizer Inc ,Health Care Industry ,Pharmaceuticals ,Biotechnology ,Biotech And Pharmaceuticals ,Business ,Business News ,